Skip to content
MARKETS / NASDAQ / CELZ
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

Creative Medical Technology Holdings, Inc. CELZ

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$6,000
▼ 45.5% YoY
$-6.0M
In brief

What this company does

In 2020, through our ImmCelz Inc. subsidiary, we began developing treatments under our ImmCelz™ platform (CELZ-100), that utilize a patient’s own extracted immune cells that are then “reprogrammed/supercharged” by culturing them outside the patient’s body with optimized cell-free factors. In June 2022, we signed an agreement with Greenstone Biosciences Inc. (“Greenstone”) for the development of a human induced pluripotent stem cell (iPSC) pipeline for our ImmCelz™ platform. In October 2022, we announced the development of our AlloStem™ Clinical Cell Line (CELZ-200), a proprietary allogenic cell line which includes a Master Cell Bank and a Drug Master File. In November 2022, we announced that the FDA had cleared the Company’s Type I Diabetes (CELZ-201 CREATE-1) Investigational New Drug (IND) application for the treatment of Type 1 Diabetes utilizing our AlloStem™ Clinical Cell Line, which will allow us to begin a Phase I/II clinical trial.

Written from the business description in Creative Medical Technology Holdings, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 20 March 2026. Every sentence was checked against that document before publication.

Growth
USD 6,000.00
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -6.0
8M16M-20M201020122014201620182020202220242025
Compound annual growth
−59.2%
−48.4%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −48.4% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−99917 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -102380.2% · Net -99916.8%
10000%20000%-50000%-100000%201020122014201620182020202220242025
ROE
FY2025 · ROE -86.5%
-50%201020122014201620182020202220242025

Each USD of equity lost 87 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Net buybacks $M Dividends $M
FY2025 · Dividends — · Net buybacks -7.2
-8M2022202320242025

Total assetsUSD 7.8M
EquityUSD 7.5M
CashUSD 7.2M
Current ratio25.97×

Equity funds 96% of total assets.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B················
Income tax $B0.00.00.00.00.00.00.00.00.00.00.0·····
Net income $B−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−2.52−3.71−3.76−0.935.61−62.69−0.82−3.50−0.03−0.010.000.000.000.000.000.00
Dividend / sh $················
Payout %················
ROE %−86.5−65.8−40.3−77.8············
Shares out B0.000.000.000.000.010.000.020.010.110.110.030.020.020.020.020.02

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 68 reconciliationsAUDITED

Reconciled in 16 of 19 fiscal years. 27 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inNevada
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image